Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
Lyrica | Pregabalin | diabetic peripheral neuropathy | Do not list | Complete | ||
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | ||
Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | ||
Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete | ||
Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending |